July 16, 2026
Circio and Avenue Biosciences jointly announce research collaboration to enhance protein secretion for gene therapy
July 2, 2026
Avenue Biosciences Expands Board of Directors with Appointment of Dr. Jens Vogel
January 12, 2026
Avenue Biosciences raises $5.7M to scale the first platform modulating the secretory pathway for enhanced therapeutic protein manufacturing
~40%
of human secretome proteins fail to produce in a standard CHO pipeline
< 20
signal peptides tested in a typical program, out of thousands available
~10-20%
of promising therapies never reach the market due to manufacturing challenges.
Signal peptide optimization significantly impacts protein biogenesis.
Each protein has specific signal peptide requirements for maximized performance.
Maintain high quality and biosimilarity for your target.
Library
Large SP libraries tailored specifically for your target of interest.
Display
Our technology measures protein secretion efficiency at individual cell level.
DNA Analysis
Identifying SP-protein combinations that drive the highest secretory output.
Validation
Top candidates characterized for enhanced expression and quality.
ANTIBODIES
FUSION PROTEINS
CELL & GENE THERAPIES
mRNA THERAPIES
ENZYMES
AI-DESIGNED PROTEINS
Our platform is a unique combination of high-throughput chemistry and synthetic biology, powered by machine learning and AI algorithms.
It is the most powerful solution to engineering N-terminal signal peptides: An element significantly underutilized in protein biologics.
Enhance any protein production system: From protein biologics and biosimilars to any mammalian protein-based biotechnology tools.
Increase the success of therapeutic and biotechnology development with precise, scalable protein engineering
Reduce time-to-market and production costs in pre-clinical therapeutic development
Gain a critical advantage and unique IP with novel molecular components
